Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy received FDA approval on June 4, 2021, as the first GLP-1 receptor agonist medication designed specifically for chronic weight management in adults with obesity or overweight status accompanied by weight-related health conditions. This approval represented a watershed moment in prescription weight loss therapy, backed by clinical trial data showing average weight loss of 15% of body weight over 68 weeks. PlexusDx now delivers compounded semaglutide—the same active ingredient—through licensed 503A pharmacies, making GLP-1 therapy available across all 50 states without insurance requirements.
The FDA Approval Date and Clinical Significance of Wegovy
The U.S. Food and Drug Administration approved Wegovy on June 4, 2021, following a rolling submission review process that evaluated months of clinical evidence. This landmark decision made semaglutide the first GLP-1 receptor agonist granted approval specifically for weight loss in non-diabetic patients, distinct from earlier approvals for diabetes management. The approval was based on the STEP clinical trial program, which enrolled over 4,500 participants and demonstrated sustained weight reduction across diverse patient populations.
Prior to the Wegovy approval, semaglutide had been available only under the brand name Ozempic for type 2 diabetes treatment since 2017. The 2021 Wegovy decision acknowledged that the same mechanism—slowing gastric emptying and enhancing satiety signals through GLP-1 receptor activation—could benefit individuals seeking weight management independent of diabetes diagnosis. This regulatory pathway opened the door for wider clinical use and expanded access to GLP-1 therapy across multiple patient groups.
How Wegovy's Approval Changed Weight Loss Treatment Options
Before June 2021, prescription weight loss options were limited to older medications like phentermine and phendimetrazine, which work through sympathomimetic pathways and carry restrictions on long-term use. Wegovy's approval introduced a new pharmacological class backed by stronger long-term efficacy data and a more favorable side effect profile for sustained treatment. The medication demonstrated not only weight reduction but also improvements in cardiovascular markers and metabolic health measures across clinical trials.
The approval accelerated development of other GLP-1 formulations, including oral semaglutide tablets and combination therapies like tirzepatide. PlexusDx now offers both injectable and oral compounded semaglutide options, providing patients with flexibility in administration routes while maintaining the proven mechanism behind Wegovy's success. This expansion reflects how regulatory approval drives pharmaceutical innovation and increases treatment accessibility.
Understanding Semaglutide: The Active Ingredient in Wegovy
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1, which regulates appetite and blood sugar. The medication is administered once weekly by subcutaneous injection in Wegovy formulations, though compounded versions may be dosed at different frequencies depending on individual treatment protocols. Semaglutide works by binding to GLP-1 receptors in the brain's appetite centers and the pancreas, leading to reduced hunger signals and improved metabolic control.
Genetic variations in GLP-1 receptor genes influence how effectively individuals respond to semaglutide therapy. PlexusDx's Precision Peptide Genetic Test identifies key variants like GLP1R rs6923761, helping predict treatment responsiveness before therapy begins. Understanding your genetic predisposition to GLP-1 pathway sensitivity allows for personalized dosing strategies that optimize outcomes while minimizing unnecessary medication exposure.
Compounded Semaglutide vs. Brand-Name Wegovy: Access and Affordability
While Wegovy became available by prescription through traditional pharmacies after June 2021, brand-name formulations carry significant costs—often exceeding $1,000 per month without insurance coverage. PlexusDx provides compounded semaglutide injections from licensed 503A compounding pharmacies starting at $149 per month, delivered across all 50 states with no membership fees or insurance requirements. Compounded medications are manufactured under strict pharmaceutical standards that ensure potency, sterility, and purity equivalent to mass-produced brands.
Both brand-name and compounded semaglutide contain the same active pharmaceutical ingredient and activate identical GLP-1 receptor pathways. The price difference reflects manufacturing and distribution efficiencies in the compounding model, not compromised quality or efficacy. PlexusDx's flat monthly pricing means your dose can increase as needed for therapeutic effect without triggering price increases—a transparent approach that removes financial uncertainty from treatment adjustments.
What the STEP Trials Revealed About Semaglutide Efficacy
The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program consisted of four randomized controlled trials published between 2021 and 2022, enrolling participants with baseline body mass index values of 30 kg/m² or higher. STEP 1, the pivotal trial, showed that participants receiving 2.4 mg semaglutide weekly achieved an average weight loss of 14.9% compared to 2.4% in the placebo group over 68 weeks. Subgroup analyses revealed consistent benefits across age groups, ethnic backgrounds, and baseline metabolic conditions.
STEP trials also documented cardiovascular benefits beyond weight loss, including reductions in systolic blood pressure and improvements in lipid profiles. Participants with prediabetes or metabolic syndrome showed particular advantage in glucose control and insulin sensitivity metrics. These comprehensive outcomes informed the FDA's approval decision and support ongoing clinical use of semaglutide for individuals seeking sustained weight management alongside metabolic health improvement.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is compounded semaglutide the same as Wegovy?
Compounded semaglutide contains the identical active ingredient as Wegovy and activates the same GLP-1 receptor pathways. Both are manufactured under strict pharmaceutical standards. The main differences are brand name, distribution channel, and cost—PlexusDx compounded versions start at $149 per month compared to brand-name Wegovy's typical $1,000+ monthly cost.
How much weight can I expect to lose with semaglutide treatment?
Clinical trial data shows average weight loss of 15% of body weight over approximately 68 weeks of treatment, with individual results ranging from 5% to 22% depending on adherence, diet, exercise, and genetic factors. PlexusDx's Precision Peptide Genetic Test can identify your GLP1R variants to help predict personalized response potential before starting therapy.
Can I use PlexusDx compounded semaglutide in all 50 states?
Yes, PlexusDx delivers compounded semaglutide injections to all 50 states from licensed 503A compounding pharmacies without requiring insurance. HSA and FSA accounts are accepted for eligible individuals, and pricing starts at $149 per month regardless of dose level.
What are the common side effects of semaglutide?
Most frequently reported side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation—typically mild to moderate and diminishing after the first 2-4 weeks of treatment. Serious adverse events are rare; however, semaglutide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
How does the Precision Peptide Genetic Test help with semaglutide treatment?
PlexusDx's Precision Peptide Genetic Test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R genes that influence weight loss pathway sensitivity. This $99 add-on test maps 14 metabolic pathways and 49 peptides to predict your individual response to GLP-1 therapy, guiding personalized dosing and combination strategies for optimal outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What is the Average Weight Loss for Ozempic?
How Soon Do Side Effects Start After Zepbound?